Detection of mutant NPM1 mRNA in acute myeloid leukemia using custom gene expression arrays

Genetic Testing and Molecular Biomarkers

Volumn 17, Issue 4, 2013, Pages 295-300

  Van Vliet, Martin H ^a   Dumee, Belinda ^a   Simons, Erik ^a   Bullinger, Lars ^b   Döhner, Konstanze ^b   Döhner, Hartmut ^b   Viëtor, Henk ^a   Löwenberg, Bob ^a   Valk, Peter J M ^a   Van Beers, Erik H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; FALSE NEGATIVE RESULT; GENE EXPRESSION; GENE MUTATION; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; RNA PROBE; SENSITIVITY AND SPECIFICITY;

ALGORITHMS; ALLELES; DNA PROBES; FEMALE; GENE EXPRESSION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY;

EID: 84875668400     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2012.0344     Document Type: Article

References (25)

1. Ammatuna E, Noguera NI, Zangrilli, et al. (2005) Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid leukemia by denaturing HPLC. Clin Chem 51:2165-2167.
2. Boissel N, Renneville A, Biggio V, et al. (2005) Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 106:3618-3620.
3. Bullinger L, Döhner K, Bair E, et al. (2004) Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 350:1605-1616.
4. Di X, Matsuzaki H, Webster TA, et al. (2005) Dynamic model based algorithms for screening and genotyping over 100 K SNPs on oligonucleotide microarrays. Bioinformatics 21:1958- 1963.
5. Döhner K, Schlenk RF, Habdank M, et al. (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 106:3740-3746.
6. Falini B, Mecucci C, Tiacci E, et al. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254-266.
7. Falini B, Martelli MP, Bolli N, et al. (2011) Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood 117:1109-1120.
8. Gale RE, Hills R, Pizzey AR, et al. (2005) Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 106:3768-3776.
9. Gorello P, Cazzaniga G, Alberti et al. (2006) Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 20:1103-1110.
10. Grimwade D, Walker H, Oliver F, et al. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92:2322-2333.
11. Kohlmann A, Bullinger L, Thiede C, et al. (2010) Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways. Leukemia 24:1216-1220.
12. Kottaridis PD, Gale RE, Frew ME, et al. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752-1759.
13. Löwenberg B, Downing JR, Burnett A (1999) Acute myeloid leukemia. N Engl J Med 341:1051-1062.
14. Mattsson G, Turner SH, Cordell J, et al. (2010) Can cytoplasmic nucleophosmin be detected by immunocytochemical staining of cell smears in acute myeloid leukemia? Haematologica 95:670-673.
15. Ribeiro AFT, Pratcorona M, Erpelinck-Verschueren C, et al. (2012) Mutant DNMT3A: a new marker of poor prognosis in acute myeloid leukemia. Blood 119:5824-5831.
16. Scholl S, Mü gge L-O, Landt O, et al. (2007) Rapid screening and sensitive detection of NPM1 (nucleophosmin) exon 12 mutations in acute myeloid leukaemia. Leuk Res 31:1205-1211.
17. Schneider F, Hoster E, Unterhalt M, et al. (2012) The FLT3ITD level has a high prognostic impact in NPM1 mutated, but not NPM1 unmutated AML with a normal karyotype. Blood 119:4383-4386.
18. Schnittger S, Schoch C, Kern W, et al. (2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106:3733-3739.
19. Suzuki T, Kiyoi H, Ozeki K, et al. (2005) Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 106:2854-2861.
20. Taskesen E, Bullinger L, Corbacioglu A, et al. (2011) Prognostic impact, concurrent genetic mutations and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 117:2469-2475.
21. Theilgaard-Mönch K, Boultwood J, et al. (2011) Gene expression profiling in MDS and AML: potential and future avenues. Leukemia 25:909-920.
22. Thiede C, Koch S, Creutzig E, et al. (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult cases with acute myeloid leukemia (AML). Blood 107:4011-4020.
23. Valk PJM, Verhaak RGW, Beijen MA, et al. (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350:1617-1628.
24. Verhaak RGW, Goudswaard CS, van Putten W, et al. (2005) Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 106: 3747-3754.
25. Wouters BJ, Löwenberg B, Erpelinck-Verschueren CAJ, et al. (2009) Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 113:3088-3091.